



Suite 518, Level 5  
165-167 Phillip Street  
Sydney NSW Australia 2000  
PO Box H100  
Australia Square NSW Australia 1215  
www.mmjgh.com.au  
info@mmjgh.com.au

## ASX RELEASE

8 November 2018

### Investment in VitaGenne

**MMJ Group Holdings Limited (ASX: MMJ) ("MMJ")** is pleased to announce that it has made a cornerstone equity investment of USD\$1 million for an 18.2% shareholding in privately-held VitaGenne Inc ("VitaGenne").

VitaGenne is a hemp-derived cannabidiol (CBD) product company focused on providing health and wellness goods in the United States. Its mission is to be the leading supplier of branded hemp-derived CBD wellness products, nutraceuticals and dietary supplements. VitaGenne's current range of products include sublingual CBD tinctures, ingestible CBD gel capsules formulated for multiple uses, topical CBD pain creams and topical CBD repairing creams.

MMJ's CEO Jason Conroy commented that "We are delighted to be the cornerstone investor in VitaGenne. The investment is our first in both hemp-derived CBD products and the United States market where we see significant opportunities for future growth."

-----

#### Investor and Media Enquiries

Jason Conroy  
Chief Executive Officer

#### About MMJ

*MMJ Group Holdings Limited (ABN 91 601 236 417) is a global cannabis investment company. MMJ owns a portfolio of minority investments and aims to invest across the full range of emerging cannabis-related sectors including healthcare, technology, infrastructure, logistics, processing, cultivation, equipment and retail. For MMJ's latest investor presentation and news, please visit: <https://www.mmjgh.com.au/investors/>*

#### Important Notice

*This announcement contains reference to certain intentions, expectations, future plans, strategy and prospects of MMJ and VitaGenne. Those intentions, expectations, future plans, strategy and prospects may or may not be achieved. They are based on certain assumptions, which may not be met or on which views may differ and may be affected by known and unknown risks. The performance and operations of MMJ and VitaGenne may be influenced by a number of factors, many of which are outside the control of MMJ and VitaGenne. No representation or warranty, express or implied, is made by MMJ or VitaGenne, or any of its directors, officers, employees, advisers or agents that any intentions, expectations or plans will be achieved either totally or partially or that any particular rate of return will be achieved. Given the risks and uncertainties that may cause MMJ's and VitaGenne's actual future results, performance or achievements to be materially different from those expected, planned or intended, recipients should not place undue reliance on these intentions, expectations, future plans, strategy and prospects. MMJ and VitaGenne do not warrant or represent that the actual results, performance or achievements will be as expected, planned or intended. Nothing in this material should be construed as either an offer to sell or a solicitation of an offer to buy or sell securities. It does not include all available information and should not be used in isolation as a basis to invest in MMJ or VitaGenne. This document does not constitute any part of any offer to sell, or the solicitation of an offer to buy, any securities in the United States or to, or for the account or benefit of any "US person" as defined in Regulation S under the US Securities Act of 1993 ("Securities Act"). MMJ's and VitaGenne's shares have not been, and will not be, registered under the Securities Act or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold in the United States or to any US person without being so registered or pursuant to an exemption from registration including an exemption for qualified institutional buyers.*